UnitedHealth shares rise on Buffett's Berkshire stake

UnitedHealth Group (UNH) shares surged nearly 13% after Warren Buffett's Berkshire Hathaway disclosed a new stake of over five million shares, signaling confidence in the beleaguered health insurer. This investment occurs despite UNH's recent operational and financial headwinds, including second-quarter adjusted earnings of $4.08 per share, down 14% year-over-year and missing analyst estimates, a reinstated 2025 full-year forecast significantly below consensus, ongoing Department of Justice scrutiny over Medicare Advantage billing practices, and the impact of a cyberattack on its Change Healthcare unit.

Analysis

UnitedHealth Group's (UNH) stock experienced a significant rally, climbing nearly 13%, driven by the disclosure of a new stake of over five million shares by Warren Buffett's Berkshire Hathaway. This vote of confidence from a prominent value investor, alongside similar moves by David Tepper and Michael Burry, contrasts sharply with the company's deteriorating fundamental picture. UNH recently reported a 14% year-over-year decline in second-quarter adjusted earnings to $4.08 per share, missing analyst estimates of $4.45, while operating earnings fell 34% and net margin contracted to 3.1%. While revenue grew a healthy 13% to $111.62 billion, the company's reinstated 2025 guidance is a major concern; it projects adjusted earnings of at least $16 per share, substantially below the $20.90 consensus, citing the impact of the Change Healthcare cyberattack. This operational weakness is compounded by significant external pressures, including an ongoing Department of Justice investigation into its Medicare Advantage billing practices and a recent CEO change, which saw the return of a former leader to navigate the financial and operational turmoil.

Key Decisions for Investors

• Investors may interpret the new Berkshire Hathaway stake as a strong contrarian signal, suggesting the market has overly punished the stock for its recent operational missteps and that current prices offer long-term value.
• Closely monitor the company's ability to meet its severely reduced 2025 adjusted EPS guidance of at least $16, as any failure to hit this lower target would indicate that the fallout from the cyberattack and operational issues is worse than anticipated.
• The ongoing Department of Justice investigation into billing practices represents a material, unquantified risk that could result in significant fines or mandated changes to its business model, warranting caution for risk-averse investors.